Our Mission

WPLab’s mission is to conduct research and educate others in order to increase awareness to families, the medical community, and lawmakers regarding autism and inflammation.

What We Do

WPLab is a not-for-profit company that conducts research and education related to immune system dysfunction in high-income countries. A current focus is the interaction between the immune system and acetaminophen (paracetamol) early in life, and how that interaction affects brain development. We have ongoing experiments using laboratory animals to try and understand the underlying causes of autism. At the same time, we work with social media and other venues to educated caregivers about what is known regarding the impact of acetaminophen (paracetamol) on the developing brain.

Who We Are

Dr. Parker is currently CEO of WPLab, Inc. He retired from Duke University after more than 27 years of research there. Best known for discovering the function of the human appendix, Dr. Parker studied biology and chemistry as an undergraduate student and went on to earn his Ph.D. in chemistry in 1992. He has been conducting scientific research since the 1980s and has published more than 140 peer-reviewed articles. His focus for the past two decades has been on factors that adversely affect immune function in high-income countries. These factors lay at the foundation of many health problems today, including allergic, autoimmune and neuropsychiatric conditions.

William Parker

Ph.D.

+View Dr.Parker's Biography

Zacharoula Konsoula

Ph.D., M.Sc.

Dr. Konsoula holds a Ph.D. in pharmacology / toxicology and has over 15 years of experience in research and development of small molecules and biologics in the pharmaceutical industry. Dr. Konsoula is a regulatory affairs expert, is experienced in various types of toxicology and safety pharmacology studies, and has a broad understanding of pharmacology and pharmacokinetics, drug metabolism and transport. Dr. Konsoula has co-authored seminal papers with WPLab Inc. describing the (a) effects of acetaminophen on laboratory animals (publishing in PLos One) and (b) a conclusive summary of evidence that acetaminophen exposure early in life causes neurodevelopmental problems in susceptible babies and children (published in Minerva Pediatrics).

Dr. Jones holds a M.A. in psychology/neuroscience and a PhD in genetics. Dr. Jones’s first work looking at the effects of early life exposure to toxins on the brain was published more than a quarter century ago, in 1996 (Brain Research, 97 (2), 207-215). He has subsequently become an accomplished drug discovery and clinical development leader with extensive strategic & operational leadership experience in R&D and product development, strategy, design of clinical trials, and product registration from a variety of pharmaceutical and academic settings. Dr. Jones has worked with Dr. Parker for more than a decade on the underlying causes of autism, co-authoring four manuscripts with him during that period, including recent work published in PloS One and in Minerva Pediatrics.